BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tivantinib: Completed Phase II enrollment

ArQule disclosed in its 3Q11 earnings that it completed enrollment of about 100 patients with unresectable HCC who have failed 1 prior systemic therapy in a double-blind, placebo-controlled, international Phase II trial to evaluate...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >